Currently, the Natco family is made up of approximately 5,000 employees. We are constantly ranked among the fastest growing pharmaceutical companies in India. Natco is well recognized for its innovation in pharmaceutical research and development.
Antineoplastic, for the treatment of advanced breast cancer, advanced neuroendocrine tumors, renal and treatment of subependymal giant cell astrocytoma.
EVEROLIMO in addition to Brazil, is already commercialized in Europe, USA and Canada.